AstraZeneca will continue to invest in India.

Despite facing some hurdles in India, Pharmaceutical giant AstraZeneca says it will continue to invest in the country.

The India arm of British-Swedish multinational with a revenue of $25.7 billion has come under the lens of SEBI for violation of regulations on fraudulent and unfair trade practices. The regulator has mandated both BSE and NSE to monitor the delisting process of the company. In an emailed response, AstraZeneca's London-based spokesperson said: 'We confirm that at every stage of the offer for sale and delisting processes, AstraZeneca has complied with the relevant SEBI regulations.'

HBL